journal article·2021-01Open access

Anti-microbial and anti-cancer activities of Mn 0.5 Zn 0.5 Dy x Fe 2-x O 4 (x ≤ 0.1) nanoparticles

Suhailah S. Al-Jameel, Suriya Rehman, Munirah A. Almessiere, Firdos A. Khan, Yassine Slimani, Najat S. Al-Saleh, Ayyar Manikandan, Ebtesam A. Al-Suhaimi, Abdulhadi Baykal

Abstract

= 0.08 and 0. 1.
Only a short abstract or summary was supplied by the source.
Source: openalex_inverted_index · Quality: short

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Magnetic Properties and Synthesis of Ferrites · Nanomaterials for catalytic reactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, College of Science, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

Department of Epidemic Diseases Research, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

Department of Biophysics, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

Department of Stem Cell Research, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

Consultant Family and Community Medicine, King Fahad Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

Department of Chemistry, Bharath Institute of Higher Education and Research (BIHER), Bharath University, Chennai, India

Biology Department, College of Science, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

Department of Nanomedicine Research, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

Funding

Imam Abdulrahman Bin Faisal University

References (60)

Show source-provided references
1. 10.1016/j.ijpharm.2018.10.06510.1016/j.ijpharm.2018.10.065 ↗
2. 10.1021/acs.nanolett.6b0226110.1021/acs.nanolett.6b02261 ↗
3. 10.1016/j.msec.2012.09.00310.1016/j.msec.2012.09.003 ↗
4. 10.1038/srep3740710.1038/srep37407 ↗
5. 10.1167/tvst.8.5.1810.1167/tvst.8.5.18 ↗
6. 10.1039/C7NR07887K10.1039/C7NR07887K ↗
7. 10.1016/j.bbrc.2015.08.02210.1016/j.bbrc.2015.08.022 ↗
8. 10.1007/s00604-018-2807-510.1007/s00604-018-2807-5 ↗
9. 10.1016/j.ijpharm.2015.07.05910.1016/j.ijpharm.2015.07.059 ↗
10. 10.1016/j.surg.2015.08.02310.1016/j.surg.2015.08.023 ↗
11. 10.1038/s41565-018-0146-710.1038/s41565-018-0146-7 ↗
12. 10.1016/j.colsurfb.2017.10.03410.1016/j.colsurfb.2017.10.034 ↗
13. 10.1016/j.jconrel.2019.08.03210.1016/j.jconrel.2019.08.032 ↗
14. 10.3390/biom1001003810.3390/biom10010038 ↗
15. 10.1080/07391102.2020.172681810.1080/07391102.2020.1726818 ↗
16. 10.1080/07391102.2020.180536010.1080/07391102.2020.1805360 ↗
17. 10.1080/07391102.2020.172275110.1080/07391102.2020.1722751 ↗
18. 10.1080/07391102.2017.141129410.1080/07391102.2017.1411294 ↗
19. 10.1080/07391102.2020.186197910.1080/07391102.2020.1861979 ↗
20. 10.1080/07391102.2020.175129610.1080/07391102.2020.1751296 ↗
21. 10.1016/j.ijpharm.2019.02.03610.1016/j.ijpharm.2019.02.036 ↗
22. 10.1016/j.ijpharm.2020.11932010.1016/j.ijpharm.2020.119320 ↗
23. 10.1016/j.ijpharm.2019.01.01810.1016/j.ijpharm.2019.01.018 ↗
24. 10.1016/j.ijpharm.2019.11877510.1016/j.ijpharm.2019.118775 ↗
25. 10.1016/j.ijbiomac.2021.02.04010.1016/j.ijbiomac.2021.02.040 ↗
26. 10.1021/acs.iecr.0c0488010.1021/acs.iecr.0c04880 ↗
27. 10.1016/j.msec.2019.04.06810.1016/j.msec.2019.04.068 ↗
28. 10.1016/j.msec.2019.11053410.1016/j.msec.2019.110534 ↗
29. 10.1016/j.msec.2019.02.08310.1016/j.msec.2019.02.083 ↗
30. 10.1002/jemt.2324510.1002/jemt.23245 ↗
31. 10.3390/nano911163510.3390/nano9111635 ↗
32. 10.3390/biom802003210.3390/biom8020032 ↗
33. 10.1016/j.ultsonch.2019.10483610.1016/j.ultsonch.2019.104836 ↗
34. 10.1016/j.msec.2020.11118610.1016/j.msec.2020.111186 ↗
35. 10.1016/j.bcab.2020.10151810.1016/j.bcab.2020.101518 ↗
36. 10.1016/j.msec.2019.04.03510.1016/j.msec.2019.04.035 ↗
37. 10.3390/pharmaceutics1211102010.3390/pharmaceutics12111020 ↗
38. 10.1088/1361-6528/abb62610.1088/1361-6528/abb626 ↗
39. 10.1080/1061186X.2020.181520910.1080/1061186X.2020.1815209 ↗
40. 10.1002/slct.20180355010.1002/slct.201803550 ↗
41. 10.1080/21691401.2019.157788610.1080/21691401.2019.1577886 ↗
42. Elsharif AM, Youssef TE, Al-Jameel SS, et al. Synthesis of an activatable tetra-substituted nickel phthalocyanines-4 (3H)-quinazolinone conjugate and its antibacterial activity. Adv Pharmacol Sci. 2019;2019:1–10.
43. 10.1007/s13204-019-01186-z10.1007/s13204-019-01186-z ↗
44. 10.1016/j.jphotobiol.2019.11172310.1016/j.jphotobiol.2019.111723 ↗
45. 10.1080/21691401.2019.162025410.1080/21691401.2019.1620254 ↗
46. 10.1016/B978-0-12-814031-4.00007-610.1016/B978-0-12-814031-4.00007-6 ↗
47. Singh R Jaisingh A Maurya IK Salunke DB. Design synthesis and bio-evaluation of C-1 alkylated tetrahydro-β-carboline derivatives as novel antifungal lead compounds. Bioorg Med Chem Lett. 2020 Feb 1;30(3):126869.10.1016/j.bmcl.2019.126869 ↗
48. 10.1016/j.ceramint.2019.01.10810.1016/j.ceramint.2019.01.108 ↗
49. 10.1002/jbio.20170030110.1002/jbio.201700301 ↗
50. 10.1021/acsnano.7b0447210.1021/acsnano.7b04472 ↗
51. 10.1021/acs.langmuir.6b0343810.1021/acs.langmuir.6b03438 ↗
52. 10.1016/j.jpcs.2015.08.00510.1016/j.jpcs.2015.08.005 ↗
53. 10.1016/j.apsusc.2018.06.02510.1016/j.apsusc.2018.06.025 ↗
54. 10.1016/j.matlet.2015.03.12010.1016/j.matlet.2015.03.120 ↗
55. 10.1016/j.ijbiomac.2015.02.04210.1016/j.ijbiomac.2015.02.042 ↗
56. Baharara J, Ramezani T, Divsalar A, et al. Induction of apoptosis by green synthesized gold nanoparticles through activation of caspase-3 and 9 in human cervical cancer cells. Avicenna J Med Biotechnol. 2016;8(2):75–83.
57. 10.1080/21691401.2018.149147610.1080/21691401.2018.1491476 ↗
58. 10.1038/srep2056410.1038/srep20564 ↗
59. 10.1155/2015/30457510.1155/2015/304575 ↗
60. Shiva I, Zhohreh S, Seyed Mohammad A, et al. Induction of growth arrest in colorectal cancer cells by cold plasma and gold nanoparticles. Arch Med Sci. 2015;11(6):1286–1295.